Nanobiotix
- Country
- 🇫🇷France
- Ownership
- -
- Employees
- 102
- Market Cap
- -
- Introduction
Nanobiotix SA is a late-stage biotechnology company, which engages in the development of therapeutic approaches to the treatment of cancer. Its technologies include NanoXray that improves the efficacy of radiation therapy against tumor cells. The company was founded by Laurent Lévy and Abdel Kader Boussaha on March 4, 2003 and is headquartered in Paris, France.
Clinical Trials
8
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (7 trials with phase data)• Click on a phase to view related trials
JNJ-90301900 (NBTXR3) Activated by Radiotherapy With or Without Cetuximab in LA-HNSCC
- Conditions
- Locally Advanced Head and Neck Squamous Cell CarcinomaAged
- Interventions
- First Posted Date
- 2021-05-19
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Johnson & Johnson Enterprise Innovation Inc.
- Target Recruit Count
- 500
- Registration Number
- NCT04892173
- Locations
- 🇺🇸
City of Hope, Duarte, California, United States
🇺🇸Memorial Radiation Oncology Medical Group Laguna Hills, Laguna Hills, California, United States
🇺🇸UCLA Hematology Oncology, Los Angeles, California, United States
NBTXR3 Activated by Radiotherapy for Patients with Advanced Cancers Treated with an Anti-PD-1 Therapy
- Conditions
- RadiotherapyImmunotherapyMicrosatellite Instability-High Solid Malignant TumourMetastasis from Malignant Tumor of LiverSquamous Cell Carcinoma of Head and NeckMetastasis from Malignant Tumor of CervixMetastasis from Malignant Melanoma of Skin (disorder)Metastatic Triple-Negative Breast CarcinomaMetastatic NSCLCMetastatic Renal Cell Carcinoma
- Interventions
- First Posted Date
- 2018-07-17
- Last Posted Date
- 2025-01-14
- Lead Sponsor
- Nanobiotix
- Target Recruit Count
- 145
- Registration Number
- NCT03589339
- Locations
- 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸Moffitt Cancer Center, Tampa, Florida, United States
🇺🇸Emory University, Atlanta, Georgia, United States
NBTXR3 Nanoparticles and EBRT or EBRT With Brachytherapy in the Treatment of Prostate Adenocarcinoma
- Conditions
- Prostate Cancer
- Interventions
- Drug: NBTXR3 activated by IMRT onlyDrug: NBTXR3 activated by Brachytherapy & IMRT
- First Posted Date
- 2016-06-20
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Nanobiotix
- Target Recruit Count
- 5
- Registration Number
- NCT02805894
- Locations
- 🇺🇸
Dana Farber Cancer Institute/Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Thomas Jefferson University Hospital, Philadelphia, Pennsylvania, United States
NBTXR3 Crystalline Nanoparticles and Stereotactic Body Radiation Therapy in the Treatment of Liver Cancers
- Conditions
- Liver Cancer
- First Posted Date
- 2016-03-28
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Nanobiotix
- Target Recruit Count
- 23
- Registration Number
- NCT02721056
- Locations
- 🇫🇷
CHU La Croix Rousse, Lyon, France
🇫🇷Institut de Cancérologie de Loraine, Nancy, France
🇫🇷CHU de NANCY, Nancy, France
NBTXR3 Crystalline Nanoparticles and Radiation Therapy in Treating Randomized Patients in Two Arms With Soft Tissue Sarcoma of the Extremity and Trunk Wall
- Conditions
- Adult Soft Tissue Sarcoma
- First Posted Date
- 2015-03-05
- Last Posted Date
- 2021-04-06
- Lead Sponsor
- Nanobiotix
- Target Recruit Count
- 180
- Registration Number
- NCT02379845
- Locations
- 🇦🇺
Capital Region Cancer Service, Canberra Hospital, Canberra, Australia
🇦🇺Chris O'Brien Lifehouse, Sydney, Australia
🇧🇪Jules Bordet Institute, Bruxelles, Belgium
- Prev
- 1
- 2
- Next
News
Nanobiotix Secures EU Regulatory Harmonization and New Patent for Cancer Radioenhancer JNJ-1900
European health authorities have reclassified JNJ-1900 (NBTXR3) from a medical device to a medicinal product, harmonizing its regulatory status with the US and other major markets.
JNJ-1900 Shows Promise in Phase 1 Trial for Advanced Pancreatic Cancer
JNJ-1900 (NBTXR3) demonstrated favorable safety and feasibility in a Phase 1 trial involving 22 patients with locally advanced or borderline resectable pancreatic cancer.
Nanobiotix's Radioenhancer JNJ-1900 Enters Phase 2 Trial for Unresectable NSCLC
Nanobiotix has dosed the first patient in the CONVERGE study, a Phase 2 trial evaluating JNJ-1900 (NBTXR3) for Stage 3 unresectable non-small cell lung cancer.
Nanobiotix Transfers US Sponsorship of NANORAY-312 to Janssen, Anticipates Key Data Readouts
Nanobiotix transferred the US sponsorship of the Phase 3 NANORAY-312 head and neck cancer study to Janssen, a key step for NBTXR3 regulatory submission.